Agenus | AGEN - Operating Profit


Agenus reported $15.05M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Agenus USD 15.05M 656K Mar/2026
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Celldex Therapeutics USD -80.62M 3.81M Jun/2026
CSL USD 2.64B 1.97B Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
Intrexon USD -60.84M 26.62M Jun/2024
J&J USD 7.48B 860M Jun/2026
Jiangsu Hengrui CNY 2.56B 302M Mar/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Merck EUR 1.1B 51M Jun/2026
Merck USD 840M 2.72B Jun/2026
Northwest Biotherapeutics USD -10.9M 3.42M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 667M 4.32B Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Veracyte USD 23.96M 4.88M Jun/2026